Lung cancer and serious bone problems

Lung Cancer and Other Solid Tumors

My Lung Cancer Has Spread to My Bones But
I Still Push Forward

XGEVA® helps protect against serious bone problems1

XGEVA® is a prescription medicine used to prevent serious bone problems in patients with bone metastases from solid tumors.1

XGEVA® is not approved for use to prevent these serious bone problems in patients with multiple myeloma.1

Serious bone problems are defined as1:

  • Broken bones (fractures)
  • The need for bone surgery
  • Radiation treatments for bone pain
  • Pressure on the spinal cord (spinal cord compression)

XGEVA® delayed serious bone problems 8.2 months longer than zoledronic acid1,2

XGEVA® delayed serious bone problems 8.2 months longer than zoledronic acid.

In studies of people with bone mets from breast cancer, prostate cancer, lung cancer, and other types of solid tumors or multiple myeloma: XGEVA® delayed serious bone problems for 27.7 months. This was 8.2 months longer than another bone-targeting medicine, zoledronic acid, also known as ZA.1,2

XGEVA® is not approved for use to prevent these serious bone problems in patients with multiple myeloma.1

Individual Results Will Vary. Discuss XGEVA® with your doctor.

For patients with bone metastases from lung and other solid tumors,

XGEVA® helps prevent serious bone problems1

In a study of 1,776 patients with bone metastases from lung cancer and other solid tumors (excluding breast and prostate cancer) or multiple myeloma, XGEVA® was no less effective than ZA in lowering the chance of serious bone problems.1

XGEVA® is not approved for use to prevent these serious bone problems in patients with multiple myeloma.1

“I focus on today, plan for tomorrow”

In addition to breast cancer and prostate cancer, XGEVA® was also studied to prevent serious bone problems in patients with bone metastases from other solid tumor cancers.2,3

This study included patients with the following solid tumors2,3:

  • Non-small cell lung cancer (12%)
  • Renal cancer (2%)
  • Small cell lung cancer (2%)

XGEVA® was also studied in other types of cancer (each with less than 5% of patients), which included1,4:

  • Biliary tract cancer
  • Bladder cancer
  • Cervical cancer
  • Colon cancer
  • Endometrial cancer
  • Esophageal cancer
  • Gastric cancer
  • Head and neck cancer
  • Hodgkin's lymphoma
  • Melanoma
  • Neuroendocrine/carcinoid cancer
  • Non-Hodgkin's lymphoma
  • Ovarian cancer
  • Pancreatic cancer
  • Rectal cancer
  • Soft tissue sarcoma
  • Testicular cancer
  • Thyroid cancer

Explore XGEVA® in other cancer types

Important Safety Information

Do not take XGEVA® if you have low blood calcium (hypocalcemia). Your low blood calcium must be treated before you receive XGEVA®. XGEVA® can significantly lower the calcium levels in your blood and some deaths have been reported. Take calcium and vitamin D as your doctor tells you to. Tell your doctor right away if you experience spasms, twitches, cramps, or stiffness in your muscles or numbness or tingling in your fingers, toes, or around your mouth.

Do not take XGEVA® if you are allergic to denosumab or any of the ingredients of XGEVA®. Serious allergic reactions have happened in people who take XGEVA®. Call your doctor or go to your nearest emergency room right away if you have any symptoms of a serious allergic reaction, including low blood pressure (hypotension); trouble breathing; throat tightness; swelling of the face, lips, or tongue, rash; itching; or hives.

What is the most important information you should know about XGEVA®?

XGEVA® contains the same medicine as Prolia® (denosumab). If you are taking XGEVA® do not take Prolia®.

Severe jaw bone problems (osteonecrosis)

Unusual thigh bone fracture

Risk of high calcium levels in patients who are still growing

Possible harm to your unborn baby

Tell your doctor if you:

While taking XGEVA®, you should:

What are the possible side effects of XGEVA®?

These are not all the possible side effects of XGEVA®. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see Full Prescribing Information.

Indication and Limitation of Use

XGEVA® is a prescription medicine used to prevent fracture, spinal cord compression, or the need for radiation or surgery to bone in patients with bone metastases from solid tumors.

XGEVA® is not used to prevent these bone problems in patients with multiple myeloma.

References:
  1. XGEVA® (denosumab) prescribing information, Amgen.
  2. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082-3092.
  3. Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679-687.
  4. Data on file, Amgen.